Mechanism of Action

Extensive research has established several key processes involved in AUS_001’s mechanism of action which involves cytoskeleton interference and p53, AP-1, NF-kB, and DNA damage-response signaling pathways. In addition, the following findings provide additional impetus into the therapeutic potential of the drug candidate.

• In vivo studies prove a strong anti-tumor effect with a mechanism that involves immune system and angiogenesis
• Response profiling (using ex vivo tissue-patient derived 3D cell cultures) demonstrated superior potency against glioblastomas, especially relative to TMZ-resistant ones
• Our results may accelerate patient selection (given BRAC2 mutated cells show increased sensitivity to our drug)
• Our drug is not expected to lead to drug resistance in cancer cells
• 5+ analogues in pipeline with similar characteristics